How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Transplantation of Multipotent Hematopoietic Stem Cells Market
- By Source of Hematopoietic Stem Cells: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Cord Blood Stem Cell Transplantation, Syngeneic Stem Cell Transplantation
- By Stem Cell Source: Bone Marrow, Peripheral Blood Stem Cells (PBSC), Umbilical Cord Blood
- By Indication: Hematologic Malignancies, Non-malignant Hematologic Disorders, Autoimmune Diseases, Genetic Disorders
- By Transplantation Procedure Type: Myeloablative Transplantation, Non-myeloablative (Reduced Intensity) Transplantation
- By End User: Hospitals, Specialized Transplant Centers, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous Stem Cell Transplantation leads By Source of Hematopoietic Stem Cells at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Transplantation of Multipotent Hematopoietic Stem Cells Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Source of Hematopoietic Stem Cells 4
Stem Cell Source 3
Indication 4
Transplantation Procedure Type 2
End User 3
Companies profiled
Fresenius Kabi AG
Thermo Fisher Scientific Inc.
Miltenyi Biotec
Lonza Group AG
STEMCELL Technologies Inc.
GE Healthcare Life Sciences
Becton Dickinson and Company
BioLife Solutions Inc.
NantKwest Inc.
Cytiva (a Danaher company)
CellGenix GmbH
Macopharma Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →STEMCELL Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GE Healthcare Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton Dickinson and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →BioLife Solutions Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →NantKwest Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cytiva (a Danaher company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CellGenix GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Macopharma Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cryo-Save AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cord Blood Registry (CBR)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Mesoblast Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,422M by 2033 · 9.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous Stem Cell Transplantation57.0
- Allogeneic Stem Cell Transplantation12.3
- Cord Blood Stem Cell Transplantation16.1
- Syngeneic Stem Cell Transplantation14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,771M → $3,664M · 9.5%
Europe$1,234M → $2,711M · 10.3%
Asia Pacific$1,127M → $2,409M · 10.0%
Latin America$697.6M → $1,514M · 10.2%
Middle East and Africa$536.6M → $1,237M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.872026
9.882027
9.882028
9.902029
9.902030
9.912031
9.932032
9.932033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Kabi AG21.5
- Thermo Fisher Scientific Inc.21.4
- Miltenyi Biotec6.8
- Lonza Group AG5.8
- STEMCELL Technologies Inc.12.3
- GE Healthcare Life Sciences4.3
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Source of Hematopoietic Stem Cells12.9%
Stem Cell Source13.8%
Indication29.7%
Transplantation Procedure Type19.8%
End User23.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe23.5
- Asia Pacific20.9
- Latin America13.1
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi AG | 76 | 95 | 83 | 76 | 94 | 83 | 85 |
| Thermo Fisher Scientific Inc. | 92 | 80 | 82 | 75 | 93 | 84 | 84 |
| Miltenyi Biotec | 74 | 86 | 79 | 71 | 81 | 70 | 77 |
| Lonza Group AG | 75 | 76 | 69 | 62 | 81 | 69 | 72 |
| STEMCELL Technologies Inc. | 61 | 53 | 72 | 58 | 51 | 65 | 60 |
| GE Healthcare Life Sciences | 66 | 58 | 52 | 70 | 59 | 52 | 60 |
| Becton Dickinson and Company | 43 | 62 | 55 | 61 | 49 | 66 | 56 |
| BioLife Solutions Inc. | 60 | 50 | 43 | 35 | 50 | 38 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Kabi AG
- Thermo Fisher Scientific Inc.
- Miltenyi Biotec
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Kabi AG | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Miltenyi Biotec | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Lonza Group AG | ◐ | ✓ | ◐ | − | ✓ | ◐ |
| STEMCELL Technologies Inc. | − | ◐ | ◐ | − | − | ◐ |
| GE Healthcare Life Sciences | ◐ | − | ◐ | ◐ | − | ◐ |
| Becton Dickinson and Company | − | ◐ | − | − | ◐ | ◐ |
| BioLife Solutions Inc. | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Kabi AG85
2Thermo Fisher Scientific Inc.84
3Miltenyi Biotec77
4Lonza Group AG72
5STEMCELL Technologies Inc.60
6GE Healthcare Life Sciences60
7Becton Dickinson and Company56
8BioLife Solutions Inc.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius Kabi AGThermo Fisher Scientific Inc.
Challenger2
Strong scale, closing on the leaders.
Miltenyi BiotecLonza Group AG
Contender2
Focused players with pockets of strength.
STEMCELL Technologies Inc.GE Healthcare Life Sciences
Niche2
Specialists in a single segment or region.
Becton Dickinson and CompanyBioLife Solutions Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Source of Hematopoietic Stem Cells in North America, then scale across Transplantation of Multipotent Hematopoietic Stem Cells Market — a $110M beachhead inside a $1.95B market.
Beachhead (SOM)$110Mobtainable near-term
Serviceable (SAM)$775Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Autologous Stem Cell Transplantation
Best fit — highest urgency & budget in Source of Hematopoietic Stem Cells.
Economic buyer76 fit
Allogeneic Stem Cell Transplantation
Strong fit — clear ROI and a fast path to value.
End user65 fit
Cord Blood Stem Cell Transplantation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Source of Hematopoietic Stem Cells in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Stem Cell Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Source of Hematopoietic Stem Cells leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Transplantation of Multipotent Hematopoietic Stem Cells Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation12%
Closed-won8%
$21.0KCAC
$104KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Transplantation of Multipotent Hematopoietic Stem Cells Market is a resilient opportunity — $7.60B by 2033, compounding at 5.3%.
TAM · 2025$5.04Btoday
TAM · 2033$7.60Bforecast
CAGR5.3%2027–2033
Cumulative$56.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.60BTotal addressable market
SAM$3.01BServiceable available market
SOM$549MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.3% CAGR
Demand compounds through 2033, outpacing GDP across Source of Hematopoietic Stem Cells.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Source of Hematopoietic Stem Cells moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.60BLarge & growingTAM by 2033 at 5.3% CAGR
$3.01BServiceable nowreachable with today’s model
$549MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.93BBear3.4% CAGR
$7.60BBase5.3% CAGR
$9.73BBull7.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Stem Cell Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Transplantation of Multipotent Hematopoietic Stem Cells Market — a $1.20B market by 2033. Plan: grow share from 9.1% to 14.1%.
Market size · 2033$1.20Btotal addressable
Market CAGR7.2%2027–2033
Target share14.1%from 9.1% today
Revenue ambition$169Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.1% | Ahead |
| Revenue | $101M | $169M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 30.0% | 43.0% | At risk |
| Customer retention | 87.0% | 96.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Source of Hematopoietic Stem Cells
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Stem Cell Source capability
A defensible second engine — invest in Stem Cell Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Source of Hematopoietic Stem Cells share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Stem Cell Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $21M capacity & capability investment
- Greenlight bolt-on M&A in Stem Cell Source
- Authorise North America expansion plan
- Fund R&D program for Source of Hematopoietic Stem Cells leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Transplantation of Multipotent Hematopoietic Stem Cells Market conversation — a $2.66B market you can size, segment and defend in minutes.
Market size · 2033$2.66Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,228+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Source of Hematopoietic Stem Cells
Goal Grow share in Source of Hematopoietic Stem Cells
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 4 mopayback period
$71K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Fresenius Kabi AGThermo Fisher Scientific Inc.Miltenyi BiotecLonza Group AGSTEMCELL Technologies Inc.GE Healthcare Life SciencesBecton Dickinson and CompanyBioLife Solutions Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Transplantation of Multipotent Hematopoietic Stem Cells Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Transplantation of Multipotent Hematopoietic Stem Cells Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Transplantation of Hematopoietic Stem Cells Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportTransperineal Access Biopsy Device Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportTransparent Wound Dressing Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportTransparent Wound Care Dressings Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportTransparent Thermostatic Water Bath Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportTransparent Self-adhesive Dressing Market
Market size, share, segmentation and regional forecast.
$308M market · 2025 base year
View reportTransparent Film Wound Dressing Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportTransparent Film Dressings Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportTransparent Dental Materials Market
Market size, share, segmentation and regional forecast.
$402M market · 2025 base year
View reportTransparent Dental Braces Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportTransparent Correction Braces Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportTransparent Ceramic Braces Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.